
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
XORTX Therapeutics Inc (XRTX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XRTX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $14.52
1 Year Target Price $14.52
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.71% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.64M USD | Price to earnings Ratio - | 1Y Target Price 14.52 |
Price to earnings Ratio - | 1Y Target Price 14.52 | ||
Volume (30-day avg) 1 | Beta -0.03 | 52 Weeks Range 0.66 - 2.98 | Updated Date 08/15/2025 |
52 Weeks Range 0.66 - 2.98 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.5% | Return on Equity (TTM) -37.96% |
Valuation
Trailing PE - | Forward PE 0.96 | Enterprise Value 2592208 | Price to Sales(TTM) - |
Enterprise Value 2592208 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.09 | Shares Outstanding 5212220 | Shares Floating 3680963 |
Shares Outstanding 5212220 | Shares Floating 3680963 | ||
Percent Insiders 2.63 | Percent Institutions 3.52 |
Upturn AI SWOT
XORTX Therapeutics Inc
Company Overview
History and Background
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing therapies to treat progressive kidney disease, with a focus on rare diseases. Founded with the goal of addressing unmet medical needs in kidney health, the company has advanced several clinical programs targeting specific genetic or disease-related causes of kidney dysfunction.
Core Business Areas
- Drug Development: Focuses on researching, developing, and commercializing pharmaceutical products for kidney diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of XORTX's drug candidates.
- Intellectual Property: Securing patents and maintaining intellectual property rights related to its drug candidates.
Leadership and Structure
Dr. Allen Nissenson, Chief Medical Officer, leads clinical development. Other key personnel include a management team focused on clinical, regulatory, and financial aspects of the company. Organizational structure consists of departments focused on research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- XRx-008 (Oxipurinol): A hypoxanthine oxidase inhibitor being developed for autosomal dominant polycystic kidney disease (ADPKD) and COVID-19 related Acute Kidney Injury. There is no market share data currently. Major competitors in the ADPKD space are Tolvaptan (Otsuka Pharmaceutical) and other therapies in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on kidney diseases is characterized by high unmet needs, significant research activity, and potential for innovation. Companies are focusing on developing targeted therapies for specific kidney disorders, addressing the limitations of existing treatments.
Positioning
XORTX Therapeutics Inc. is positioned as a company developing novel therapies for progressive kidney disease, particularly in areas with limited treatment options. Its competitive advantage lies in its focus on specific genetic and disease-related targets and its potential to develop first-in-class therapies.
Total Addressable Market (TAM)
The total addressable market (TAM) for ADPKD therapies is estimated to be in the billions of dollars. XORTX Therapeutics Inc. is positioned to capture a portion of this market with its XRx-008 drug candidate, contingent upon successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Focus on unmet needs in kidney disease
- Proprietary drug development platform
- Experienced management team
- Potential for first-in-class therapies
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- No currently approved products
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new kidney disease indications
- Advancements in biomarker development
- Regulatory pathways for orphan drugs
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Adverse regulatory decisions
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- OTSU
Competitive Landscape
XORTX Therapeutics Inc. faces competition from established pharmaceutical companies with approved therapies for kidney diseases and from other biotech companies developing novel treatments. XORTX's advantage lies in its focus on specific genetic and disease-related targets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by advancement of clinical programs and securing funding for research and development.
Future Projections: Future growth is dependent on clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates vary and depend on these factors.
Recent Initiatives: Recent initiatives include advancing XRx-008 into later-stage clinical trials and exploring new partnerships.
Summary
XORTX Therapeutics Inc. is a development-stage biopharmaceutical company focusing on kidney diseases. Its strength lies in its pipeline of novel therapies and a focus on unmet needs. The company's success depends on the outcomes of its clinical trials and regulatory approvals. XORTX is dependent on a number of key clinical trials in their pipeline. It needs to expand it's pipeline to include other therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XORTX Therapeutics Inc
Exchange NASDAQ | Headquaters Calgary, AB, Canada | ||
IPO Launch date 2018-11-28 | Founder, CEO, President & Director Dr. Allen Warren Davidoff Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.xortx.com |
Full time employees - | Website https://www.xortx.com |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.